Treace's Percutaneous Pinning Platform Powers Q4 2025 Results Announcement

Treace Medical Concepts, Inc. (NasdaqGS: TMCI), a pioneer in advanced surgical correction technologies, is set to disclose its fourth quarter and full-year 2025 financial results on February 27, 2026, prior to market open. The announcement marks a significant milestone for the medical technology innovator, whose percutaneous-based treatment systems have transformed surgical approaches to complex foot deformities.

Expanding Portfolio of Minimally Invasive Solutions

The company’s product ecosystem reflects its commitment to advancing surgical precision. Beyond its flagship Lapiplasty 3D Bunion Correction System—which uniquely addresses the three-dimensional nature of bunion deformities—Treace offers the Adductoplasty Midfoot Correction System for reproducible midfoot correction. The company has further strengthened its minimally invasive offerings with the Nanoplasty 3D system and the Percuplasty Percutaneous 3D Bunion Correction System, both designed to deliver reliable outcomes through advanced percutaneous pinning and minimally invasive techniques. These innovations are complemented by the SpeedMTP System and the expanding SpeedPlate rapid compression implant platform, which continues to reach new clinical applications.

Addressing a Massive Unmet Need

With approximately 67 million Americans affected by bunion deformities and an estimated 1.1 million viable surgical candidates annually, Treace operates within a substantial market opportunity. Bunions, which originate from an unstable joint in the middle of the foot and progress across three spatial dimensions, demand innovative surgical solutions. The company’s integrated approach—combining instruments, implants, and proprietary surgical methodologies—directly addresses the root cause of these deformities, enabling patients to return to active lifestyles more effectively than traditional approaches.

Strategic Digital Integration

Recognizing that surgical innovation extends beyond hardware, Treace has developed IntelliGuide, a patient-specific digital planning and cut guide platform. This technology empowers surgeons with advanced pre-operative planning capabilities, enhancing precision and reproducibility across procedures.

Earnings Discussion and Investor Access

Company leadership will conduct an earnings briefing beginning at 8:00 am ET on Friday, February 27, 2026, to discuss financial performance and operational developments. Investors and market participants interested in participating may register in advance to receive dial-in information and access codes. A live webcast and archived recording will be available through Treace’s investor relations website, ensuring accessibility for a broad audience.

The company maintains an active investor relations presence, regularly updating its website with material developments and financial disclosures relevant to shareholders and prospective investors.

About Treace Medical Concepts, Inc. — Treace is a medical technology company dedicated to advancing the surgical management standard for bunion and related midfoot deformities. Through its portfolio of patented systems and innovative digital solutions, Treace empowers surgeons to deliver superior clinical outcomes while expanding patient access to effective treatment options.